Statistical methods for elimination of guarantee-time bias in cohort studies: A simulation study

BMC Medical Research Methodology

Volumn 17, Issue 1, 2017, Pages

  Cho, In Sung ^a   Chae, Ye Rin ^a   Kim, Ji Hyeon ^b   Yoo, Hae Rin ^b   Jang, Suk Yong ^c   Kim, Gyu Ri ^a   Nam, Chung Mo ^b  

^a Yonsei University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Eulji University   (South Korea)

Author keywords

Cox regression; Guarantee time bias; Landmark method; Time dependent Cox regression

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; ROSIGLITAZONE;

ALGORITHM; CHEMICALLY INDUCED; COHORT ANALYSIS; COMPUTER SIMULATION; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; STATISTICAL BIAS; STATISTICAL MODEL; TIME FACTOR;

ALGORITHMS; BIAS; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; COMPUTER SIMULATION; HUMANS; HYPOGLYCEMIC AGENTS; LIVER NEOPLASMS; MODELS, STATISTICAL; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; THIAZOLIDINEDIONES; TIME FACTORS;

EID: 85027976016     PISSN: None     EISSN: 14712288     Source Type: Journal    
DOI: 10.1186/s12874-017-0405-6     Document Type: Article

References (36)

1. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing physicians study. N Engl J Med. 1989;321:129-35.
2. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA. 2006;295(3):306-13.
3. Manson JE, Stampfer MJ, Colditz GA, Willett WC, Rosner B, Speizer FE, Hennekens CH. A prospective study of aspirin use and primary prevention of cardiovascular disease in women. JAMA. 1991;266(4):521-7.
4. Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, Rosenson RS, Williams CD, Wilson PW, Kirkman MS. Aspirin for primary prevention of cardiovascular events in people with diabetes. Circulation. 2010;121(24):2694-701.
5. Ridker PM, Cook NR, Lee I-M, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352(13):1293-304.
6. Seshasai SRK, Wijesuriya S, Sivakumaran R, Nethercott S, Erqou S, Sattar N, Ray KK. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med. 2012;172(3):209-16.
7. Hwang I-C, Jeon J-Y, Kim Y, Kim HM, Yoon YE, Lee S-P, Kim H-K, Sohn D-W, Sung J, Kim Y-J. Association between aspirin therapy and clinical outcomes in patients with non-obstructive coronary artery disease: a cohort study. PLoS One. 2015;10(6):e0129584.
8. Ofman P, Petrone AB, Peralta A, Hoffmeister P, Albert CM, Djousse L, Gaziano JM, Rahilly-Tierney CR. Aspirin Use and Risk of Atrial Fibrillation in the Physicians' Health Study. J Am Heart Assoc. 2014;3(4):e000763.
9. Ekström N, Cederholm J, Zethelius B, Eliasson B, Fhärm E, Rolandsson O, Miftaraj M, Svensson A-M, Gudbjörnsdottir S. Aspirin treatment and risk of first incident cardiovascular diseases in patients with type 2 diabetes: an observational study from the Swedish National Diabetes Register. BMJ Open. 2013;3(4):e002688.
10. King A, Shipley M, Markus H, Investigators A. The effect of medical treatments on stroke risk in asymptomatic carotid stenosis. Stroke. 2013;44(2):542-6.
11. Azoulay L, Dell'Aniello S, Simon TA, Langleben D, Renoux C, Suissa S. A net clinical benefit analysis of warfarin and aspirin on stroke in patients with atrial fibrillation: a nested case-control study. BMC Cardiovasc Disord. 2012;12(1):49.
12. Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, Jankowski J, La Vecchia C, Meyskens F, Senn HJ. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. The lancet oncology. 2009;10(5):501-7.
13. Dubé C, Rostom A, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson M, Moher D. The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the US Preventive Services Task Force. Ann Intern Med. 2007;146(5):365-75.
14. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci. 1997;94(7):3336-40.
15. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, RN DB. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998;93(5):705-16.
16. Fraser D, Sullivan F, Thompson A, McCowan C. Aspirin use and survival after the diagnosis of breast cancer: a population-based cohort study. Br J Cancer. 2014;111(3):623-7.
17. Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst. 2007;99(8):608-15.
18. Mc Menamin ÚC, Cardwell CR, Hughes CM, Murray LM. Low-dose aspirin and survival from lung cancer: a population-based cohort study. BMC Cancer. 2015;15(1):911.
19. Cardwell CR, Kunzmann AT, Cantwell MM, Hughes C, Baron JA, Powe DG, Murray LJ. Low-dose aspirin use after diagnosis of colorectal cancer does not increase survival: a case-control analysis of a population-based cohort. Gastroenterology. 2014;146(3):700-8. e702
20. Suissa S, Azoulay L. Metformin and the risk of cancer. Diabetes Care. 2012;35(12):2665-73.
21. Suissa S. Immortal time bias in pharmacoepidemiology. Am J Epidemiol. 2008;167(4):492-9.
22. Lévesque LE, Hanley JA, Kezouh A, Suissa S. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ. 2010;340:b5087.
23. Giobbie-Hurder A, Gelber RD, Regan MM. Challenges of guarantee-time bias. J Clin Oncol. 2013;31(23):2963-9.
24. Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf. 2007;16(3):241-9.
25. Nam CM, Zelen M. Comparing the survival of two groups with an intermediate clinical event. Lifetime Data Anal. 2001;7(1):5-19.
26. Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. Am J Respir Crit Care Med. 2003;168(1):49-53.
27. Samet JM: Measuring the effectiveness of inhaled corticosteroids for COPD is not easy! In.: Am Thoracic Soc; 2003.
28. Suissa S, Ernst P. Bias in observational study of the effectiveness of nasal corticosteroids in asthma. J Allergy Clin Immunol. 2005;115(4):714-9.
29. Mi X, Hammill BG, Curtis LH, Lai ECC, Setoguchi S. Use of the landmark method to address immortal person-time bias in comparative effectiveness research: a simulation study. Stat Med. 2016;35(26):4824-36.
30. Ihaka R, Gentleman R. R: a language for data analysis and graphics. J Comput Graph Stat. 1996;5(3):299-314.
31. Han E, Jang S-Y, Kim G, Lee Y-h, Choe EY, Nam CM, Kang ES. Rosiglitazone use and the risk of bladder cancer in patients with type 2 diabetes. Medicine. 2016;95(6):e2786.
32. Kim G, Jang SY, Han E, Lee Y. Park Sy, Nam CM, Kang ES: Effect of statin on hepatocellular carcinoma in patients with type 2 diabetes: A nationwide nested case-control study. Int J Cancer. 2017;140(4):798-806.
33. SAS Institute Inc. Base SAS® 9.4 procedures guide: statistical procedures. Cary: SAS Institute Inc; 2014.
34. Van Houwelingen HC. Dynamic prediction by landmarking in event history analysis. Scand J Stat. 2007;34(1):70-85.
35. Nicolaie M, Houwelingen J, Witte T, Putter H. Dynamic prediction by landmarking in competing risks. Stat Med. 2013;32(12):2031-47.
36. Klein JP, Moeschberger ML: Survival analysis: techniques for censored and truncated data: Springer Science & Business Media; 2005.